Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037219 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
A Phase 2 study of Candidiasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00037219: Completed Phase 2 study of Candidiasis, sponsored by Pfizer.
NCT00037219 is a Phase 2 study of Candidiasis that has completed, run by Pfizer. The registered enrollment target is 120 participants, below the 314-participant average among 7 other Candidiasis trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037219, a Phase 2 study of Candidiasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.
Conditions Studied
Interventions
- DRUG Anidulafungin, VER002
Study Locations (1)
Pennsylvania
- Versicor, Inc. - King of Prussia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-08 |
| Est. Completion | 2002-11 |
| Phase | Phase 2 |
What the finished NCT00037219 record still lists
NCT00037219 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 314-participant average among 7 other Candidiasis trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Candidiasis appearing as the primary indexed condition, and to 1 intervention - of which Anidulafungin, VER002 is the first listed.
NCT00037219 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00037219 about?
NCT00037219 is a clinical study titled "The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.". Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.
What is the current status of trial NCT00037219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2001-08. Estimated completion is 2002-11.
What conditions does trial NCT00037219 study?
This clinical trial studies the following conditions: Candidiasis.
What interventions are being tested in trial NCT00037219?
The interventions under investigation include: Anidulafungin, VER002 (DRUG).
Who is sponsoring clinical trial NCT00037219?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00037219 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidiasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
COMPLETED · Phase 2
-
A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
COMPLETED · Phase 1
-
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
COMPLETED · Phase 3
-
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
COMPLETED · Phase 4
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
-
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia